Profile image
Story Views

Last Hour:
Last 24 Hours:

Cancer Immunotherapies Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2016 – 2022

Sunday, February 12, 2017 23:12
% of readers think this story is Fact. Add your two cents.

Global Cancer Immunotherapies Market analysis is provided for Global Cancer Immunotherapies Market including Landscape, Introduction and Key Marketed Products. Global Cancer Immunotherapies Market to 2022 – Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market. The leading indications in terms of cancer immunotherapy product development are breast cancer, melanoma, non-small-cell lung cancer (NSCLC) and ovarian cancer, which are the focus of this Cancer Immunotherapies Market report.

 Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A few cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signalling pathways are deregulated in most cancers. These signalling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

Browse more detail information about Cancer Immunotherapies Market report at:

Key Marketed Products:

  • Rituxan/MabThera – Roche
  • Revlimid (lenalidomide) – Celgene
  • Yervoy (ipilimumab) – Bristol-Myers Squibb
  • Opdivo (nivolumab) – Bristol-Myers Squibb
  • Keytruda (pembrolizumab) – Merck & Co.
  • Pomalyst (pomalidomid) – Celgene
  • Gardasil/Gardasil 9 (human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine-prophylactic vaccine) – Merck & Co.
  • Provenge (sipuleucel-T) – Valeant Pharmaceuticals

And many more…………

Get a PDF Sample of Cancer Immunotherapies Market Research Report at:


The cancer immunotherapies market already consists of some commercially successful products.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?

The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.

  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?

The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.

  • Which products are forecast to drive this substantial degree of growth?
  • Will generic competition have a significant impact on the market over the forecast period?

The company landscape is growing increasingly competitive.

  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • What are the drivers of growth for key companies in the market?
  • How dependent are the key companies on this disease cluster for revenue?
  • Which companies rely heavily on this disease cluster for revenue?

Have any query? ask our expert @


Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which includes breast cancer, melanoma, NSCLC and ovarian cancer.
  • Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from cancer immunotherapy products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals.


Purchase a Copy Of this Report @


About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.